ADAPTIVE BIOTECHNOLOGIES CORPORATION Debt Securities, Available-for-sale, Amortized Cost, Current
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Debt Securities, Available-for-sale, Amortized Cost, Current of $174.51 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $174.51M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $140.76M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $156.25M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $157.52M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2026-06-30 | $174.51M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $140.76M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $156.25M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $157.52M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $154.67M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $142.74M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $174.19M 10-K · filed 2026-02-26 |
| 2024-09-30 | $204.76M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $232.24M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $237.75M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $281.12M 10-K · filed 2025-03-03 |
| 2023-09-30 | $282.67M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $308.88M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $347.99M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $412.28M 10-K · filed 2024-02-29 |
| 2022-09-30 | $295.69K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $311.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $250.45M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $214.12M 10-K · filed 2023-02-14 |
| 2021-09-30 | $292.56M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $413.96M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $540.02M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $564.04M 10-K · filed 2022-02-15 |
| 2020-09-30 | $336.84M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $203.76M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $340.95M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $479.79M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |